NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
8 trialsNCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT00003526 2020-12-17
Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin
Burzynski Research Institute
Phase 2 Terminated
NCT00066781 2017-04-04
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00936702 2017-03-21
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00873119 2015-07-28
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics
Phase 2 Completed
NCT00360360 2013-12-04
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193609 2013-11-11
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed